Overview
Opsumit is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to delay disease progression in cases of pulmonary arterial hypertension (PAH). Opsumit may be referred to by its drug name…

Overview
Opsynvi, approved by the U.S. Food and Drug Administration (FDA), is indicated for the chronic treatment of adults with pulmonary arterial hypertension (PAH, WHO group 1) at WHO functional class 2 and 3…

Overview
Orenitram is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise capacity in cases of pulmonary arterial hypertension (PAH). Orenitram may be referred to by its drug…

Overview
Remodulin is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise capacity in cases of pulmonary arterial hypertension (PAH). Remodulin is sometimes prescribed when…

Overview
Revatio is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise and delay disease progression in cases of pulmonary arterial hypertension. Revatio may be referred to by…

Overview
Tadliq is approved by the U.S. Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH) Group 1. It is prescribed to improve exercise ability in individuals with PAH. Tadliq…

Overview
Tracleer is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise capacity and limit disease progression in adults with pulmonary arterial hypertension (PAH). Tracleer…

Overview
Tyvaso is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise capacity in cases of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with…

Overview
Uptravi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to delay disease progression and reduce the risk of hospitalization in cases of pulmonary arterial hypertension (PAH)…

Overview
Veletri is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise capacity in cases of pulmonary arterial hypertension (PAH). Veletri may be referred to by its drug name…

Overview
Winrevair is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with pulmonary arterial hypertension (PAH), also known as World Health Organization (WHO) Group 1 pulmonary…

Overview
Yutrepia is approved by the U.S. Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. It is prescribed to…